BioCryst Pharmaceuticals (BCRX) Expected to Announce Quarterly Earnings on Monday

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Monday, February 24th. Analysts expect the company to announce earnings of ($0.07) per share and revenue of $131.10 million for the quarter. Individual that wish to listen to the company's earnings conference call can do so using this link.

BioCryst Pharmaceuticals Price Performance

Shares of BCRX remained flat at $9.39 during trading hours on Thursday. The stock had a trading volume of 3,415,368 shares, compared to its average volume of 2,822,247. BioCryst Pharmaceuticals has a one year low of $4.03 and a one year high of $9.50. The company has a market cap of $1.94 billion, a PE ratio of -15.39 and a beta of 1.75. The stock has a 50 day moving average price of $7.94 and a 200-day moving average price of $7.81.

Wall Street Analysts Forecast Growth

Several research firms have commented on BCRX. Barclays increased their target price on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an "equal weight" rating in a research report on Tuesday, November 5th. Royal Bank of Canada reiterated an "outperform" rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. Needham & Company LLC boosted their target price on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a "buy" rating in a report on Monday, January 13th. JMP Securities reaffirmed a "market outperform" rating and set a $18.00 price target on shares of BioCryst Pharmaceuticals in a research note on Friday, January 31st. Finally, Evercore ISI lifted their price target on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an "outperform" rating in a report on Monday, January 13th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, BioCryst Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $15.50.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.